| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System |
Recent Updates
Recently added Catalysts
4D Molecular Therapeutics, Inc.$12.31
-0.58 (-4.5%)
C 56Pipeline Score Fair Value Biotech · Commercial
Market Cap
449.58 M
EPS
-2.66
P/E Ratio
-
Value Trade
8.97 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
3.05 M
R&D Expenses
64.98 M
Operating CF
-68.13 M
Total Assets
512.90 M
Total Liabilities
61.07 M
Equity
451.84 M
D/E Ratio
12,345
-10.14 %
Week
-12.69 %
1 Month
-4.76 %
3 Month
-16.5 %
6 Month
-69.24 %
5 Year
-78.5 %
All Time
Cash Data
Cash Position
390.89 M
Monthly Burn
22.71 M
Runway
15.3 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
683.60 K
52 Week Range
3.37 - 12.34
% held by Insiders
10.32 %
% held by Institutions
90.72 %
Enterprise Value
79.22 M
Total Shares
52.26 M
Short %
29.88 %
Float Shares
44.53 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for 4D Molecular Therapeutics, Inc.
216Total events
3Upcoming
70Tier-1 (high impact)
2021 – 2028Coverage
Upcoming catalysts 3
Event history 213
Q3 2026
◆Trial Initiation4D-150Trial
Initiation of Phase 3 trial of 4D-150 in diabetic macular edema
diabetic macular edemasource ↗
Q3 2026
◆Enrollment Milestone4D-150Trial
Final patient randomization expected for 4FRONT-2
wet age-related macular degenerationsource ↗
Jun 29, 2026
▲Debt Royalty FinancingCorporate
Strategic credit facility agreement with Hercules Capital for up to $200 million
Jun 29, 2026
▲Enrollment Complete4D-150Trial
Enrollment completed for 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD
wet age-related macular degenerationsource ↗
Jun 2026
◆Full Results4D-150Clinical Data
2-year Phase 2b data from PRISM trial expected in mid-2026
wet age-related macular degenerationsource ↗
Q2 2026
◆Timing Guidance4D-710Presentation
Additional updates on 4D-710 expected in second half of 2026
cystic fibrosis lung diseasesource ↗
Mar 2026
▲Enrollment Complete4D-150Trial
4FRONT-1 randomization completed (N=523)
wet age-related macular degenerationsource ↗
Drug Pipeline Intelligence
C56
Pipeline Score $1.2B
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored2.6x
rNPV / MCap Top 84%
Micro Cap (rank 147 of 911)
Percentile Rank4D Molecular Therapeutics, Inc. carries a moderate pipeline score (56/100), with $3.5B risk-adjusted pipeline value, led by 4D-150 IVT in Neovascular Age-Related Macular Degeneration (nAMD) (Phase 3), across $51B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D-150 IVT Monoclonal antibody | Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | NCT06864988 | 64% | $2.4B | ACTIVE NOT_RECRUITING | 480 | FAST | B (68) | Jun 1, 2028 | MODERATE_RISK | LOW Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
4D-710 Rare Pediatric | cystic fibrosis lung disease | Phase 1 | 2025-12-17 | well tolerated; achieved physiologically relevant levels of CFTR expression Read More | 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease Read More | |
4D-710 Rare Pediatric | cystic fibrosis lung disease | Phase 1 | 2025-12-17 | well tolerated; achieved physiologically relevant levels of CFTR expression Read More | 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease Read More | |
4D-710 Rare Pediatric | cystic fibrosis lung disease | Phase 1 | 2025-12-17 | well tolerated; achieved physiologically relevant levels of CFTR expression Read More | 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FDMT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FDMT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FDMT4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics (FDMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in Montreal from July 15-18, 2026. The presentation will focus on their lead product candidate, 4D-150, which is in Phase 3 development for treating wet age-related macular degeneration. This therapy aims to provide sustained delivery of anti-VEGF biologics, significantly reducing treatment frequency for patients.
Read more →FDMT▲ +11%on this newsshared move
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
4D Molecular Therapeutics has entered into a strategic credit facility agreement with Hercules Capital for up to $200 million. This non-dilutive capital is expected to bolster the company's financial position and support the development of its lead product candidate, 4D-150, currently in Phase 3 for wet AMD and DME. The initial drawdown of $20 million has already been completed, with additional funds available upon achieving specific milestones.
Read more →FDMT▲ +11%on this newsshared move
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics has completed global enrollment for its Phase 3 clinical trial, 4FRONT-2, evaluating the efficacy of 4D-150 in treating wet age-related macular degeneration. The trial saw over-enrollment, with final patient randomization expected by Q3 2026. Topline data from the trial is anticipated in H2 2027, marking a significant step in addressing the treatment burden associated with wet AMD.
Read more →FDMT4DMT Announces New Employment Inducement Grants
4DMT Announces New Employment Inducement Grants
Read more →FDMT4DMT to Participate in Upcoming Investor Conferences
4DMT to Participate in Upcoming Investor Conferences
Read more →FDMTDMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • 4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 •
4D Molecular Therapeutics (FDMT) reported its Q1 2026 financial results, highlighting the completion of randomization for its Phase 3 clinical trial of 4D-150 in wet age-related macular degeneration. The company anticipates topline data from this study in H1 2027 and plans to complete enrollment for its 4FRONT-2 trial by H2 2026. A strong cash reserve of $458 million is projected to sustain operations into the latter half of 2028, while R&D expenses have notably increased due to ongoing trial commitments. With significant data expected in the coming years, the company aims to advance its clinical pipeline despite current losses increasing compared to previous quarters.
Read more →FDMT4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (FDMT) reported its Q1 2026 financial results, highlighting the completion of enrollment in its Phase 3 clinical trial for 4D-150 targeting wet AMD. The company anticipates topline data from this trial in H1 2027 and plans to complete enrollment for another trial by H2 2026. With $458 million in cash reserves, 4DMT expects to sustain operations through 2028 while continuing to advance its clinical programs.
Read more →FDMTScrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
The article discusses the future of biopharma, specifically focusing on research and development innovation expected in 2026. It highlights the intersection of cutting-edge progress and practical considerations in the industry. The content is part of a series that examines various aspects of biopharma's evolution.
Read more →FDMTDMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initia
4D Molecular Therapeutics (Nasdaq: FDMT) reported its full-year financial results for 2025, highlighting successful developments in its clinical trials and financial stability. The company completed enrollment in the Phase 3 4FRONT-1 trial for wet AMD ahead of schedule, with topline data anticipated in the first half of 2027. Financially, 4DMT holds $514 million in cash, enough to extend operations into the latter half of 2028. The company also formed a strategic partnership with Otsuka, which is expected to provide substantial funding for ongoing development activities.
Read more →FDMT4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics reported strong operational progress in 2025, including the completion of enrollment for its Phase 3 trial of 4D-150 for wet AMD. The company has a robust cash position of $514 million, expected to fund operations into 2028. Upcoming milestones include topline data from the Phase 3 trial in H1 2027 and continued development of its CF therapy.
Read more →FDMT4DMT to Participate in Upcoming Investor Meetings
4D Molecular Therapeutics (FDMT) announced its participation in upcoming investor conferences in March. The company is focused on developing disease-targeted therapeutics, with its lead product candidate, 4D-150, currently in Phase 3 for treating wet age-related macular degeneration. The firm aims to reduce treatment burdens associated with current therapies. An archived webcast of the presentations will be available on their website.
Read more →FDMT4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD
4D Molecular Therapeutics has completed enrollment for its phase 3 trial, 4FRONT-1, evaluating the gene therapy 4D-150 for wet age-related macular degeneration. The study compares 4D-150 to aflibercept in treatment-naïve patients and aims to demonstrate noninferiority in visual acuity after 52 weeks. Results from this trial are anticipated in early 2027.
Read more →FDMT4DMT Completes Enrollment for Phase 3 Trial of 4D-150 for Wet AMD
4D Molecular Therapeutics has successfully completed enrollment for its Phase 3 trial, 4FRONT-1, evaluating 4D-150 in wet AMD patients. The trial has exceeded 500 participants, highlighting strong interest in the treatment. The primary endpoint focuses on noninferiority in vision outcomes, with topline data expected in early 2027. A second trial, 4FRONT-2, is also underway.
Read more →FDMT4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics has completed enrollment for its Phase 3 clinical trial, 4FRONT-1, evaluating 4D-150 in patients with wet age-related macular degeneration (AMD). The trial achieved high enrollment in just 11 months, reflecting strong enthusiasm from both investigators and patients. The company aims to shift treatment paradigms by reducing the burden of repeated injections for wet AMD patients. Topline data from the trial is expected in H1 2027.
Read more →FDMT4DMT Announces New Employment Inducement Grants - January 17, 2026
4D Molecular Therapeutics announced the granting of 23,600 Restricted Stock Units to four new non-executive employees as part of its 2025 Employment Inducement Award Plan. This initiative aims to attract talent to support the company's innovative therapeutic developments, including its lead product candidate, 4D-150, which is in Phase 3 trials for treating wet age-related macular degeneration.
Read more →FDMT▲ +8.1%on this news
4DMT Provides Company Update and Anticipated Development Milestones for 2026
4D Molecular Therapeutics (FDMT) provided an update on its corporate strategies and anticipated milestones for 2026. The company is focused on the late-stage development of its lead product, 4D-150, for retinal vascular diseases, while also enhancing its leadership team to support commercialization efforts. With a solid financial foundation, 4DMT aims to transform treatment paradigms in retinal therapeutics.
Read more →FDMT▼ -20.1%on this news
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
4D Molecular Therapeutics announced positive interim results from the Phase 1 AEROW trial of 4D-710, a treatment for cystic fibrosis lung disease. The data indicated that the selected Phase 2 dose was well tolerated and achieved relevant CFTR expression levels. Clinical benefits were observed across various lung function measures, suggesting 4D-710's potential as a transformative therapy for cystic fibrosis.
Read more →FDMTThe gene therapy shift: A closer look at the science powering next-generation retinal treatments
The article discusses the advancements in gene therapy for retinal diseases, particularly neovascular age-related macular degeneration (nAMD). It highlights the potential of gene therapy to provide long-lasting treatment solutions, reducing the need for frequent injections. Ongoing clinical trials are exploring various gene therapy candidates, which have shown promising efficacy and safety profiles. However, concerns regarding inflammation and variability in dosing remain critical considerations.
Read more →FDMT4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
4D Molecular Therapeutics (FDMT) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The management team will also hold one-on-one meetings during the event. The company is known for its late-stage biotechnology developments, including its lead product candidate 4D-150 for retinal diseases.
Read more →FDMT“Speed is survival”: Inside 4D Molecular Therapeutics bid to scale genetic medicine
4D Molecular Therapeutics (4DMT), founded by David Kirn, focuses on scaling genetic medicine through directed evolution of viral vectors. The company targets larger markets like wet AMD and cystic fibrosis, aiming for sustainable treatments. Recent positive trial data supports their innovative approach, while strategic partnerships enhance their development capabilities. However, manufacturing and regulatory challenges remain critical considerations.
Read more →FDMT4DMT Company Updates
The article provides an overview of recent updates related to 4DMT and other companies in the ophthalmology sector. It highlights various developments, including FDA approvals and product launches. The content is primarily focused on industry advancements without specific emphasis on 4DMT's unique contributions or challenges.
Read more →FDMT4D-150 maintains visual acuity in wet AMD at 2 years
The gene therapy 4D-150 has shown promising results in maintaining visual acuity in patients with wet age-related macular degeneration for two years. According to the phase 1/2 PRISM trial, patients experienced a reduction in the need for supplemental injections. The therapy was well-tolerated, with no new safety concerns reported. Ongoing trials are expected to further evaluate its efficacy and safety.
Read more →FDMTCF Foundation adds to investment in 4DMT’s CF gene therapy
The Cystic Fibrosis Foundation has invested up to $11 million in 4D Molecular Therapeutics to support the development of 4D-710, an inhaled gene therapy for cystic fibrosis. This funding will aid ongoing clinical trials, including a Phase 1/2 study called AEROW, and plans for a future Phase 3 study. The therapy aims to provide a durable treatment option for patients with unmet pulmonary needs.
Read more →FDMT4DMT’s eye gene therapy cuts need for injections that treat diabetic macular edema
4D Molecular Therapeutics has developed a gene therapy that significantly reduces the number of injections required for patients suffering from diabetic macular edema. This therapy is a variant of Regeneron's Eylea, aiming to enhance treatment efficacy and patient comfort. The innovation could lead to better adherence to treatment regimens.
Read more →FDMTA new approach to DME treatment
The FDA has granted RMAT designation to 4D-150, a gene therapy for diabetic macular edema (DME). This designation aims to expedite the treatment process, potentially reducing the need for frequent eye injections. Early studies show that 4D-150 could significantly lower the treatment burden while improving vision outcomes for patients. The therapy is designed to provide long-term benefits with a single injection.
Read more →FDMTARVO 2025: Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
At the 2025 ARVO meeting, Dr. Christine Kay presented interim results from the PRISM trial, which evaluates the gene therapy 4D-150 for wet AMD. The phase 2b study focuses on patients with severe disease and those recently diagnosed. The 4D-150 vector aims to enhance retinal cell transduction and reduce treatment burden.
Read more →FDMTFDA grants RMAT designation to 4DMT for DME gene therapy
4D Molecular Therapeutics has been granted RMAT designation by the FDA for its gene therapy candidate 4D-150, aimed at treating diabetic macular edema (DME). This designation is based on promising interim clinical data indicating the therapy's potential to address unmet medical needs. The company plans to conduct a phase 3 trial to support a future Biologics License Application.
Read more →FDMTFirst Patients Enrolled in 4DMT’s Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
4D Molecular Therapeutics has enrolled the first patients in the Phase 3 4FRONT-1 trial for 4D-150, targeting wet AMD. This trial aims to demonstrate noninferiority in visual acuity compared to aflibercept. The treatment promises multi-year relief from injections, potentially transforming patient care. A second trial, 4FRONT-2, is set to begin in Q3 2025.
Read more →FDMT4DMT to Participate in 8th Annual Evercore Healthcare Conference
4D Molecular Therapeutics (FDMT) will participate in the 8th Annual Evercore Healthcare Conference, where its management team will engage in a fireside chat and hold one-on-one meetings. The company is known for its late-stage biotechnology advancements, particularly in therapies for retinal diseases and cystic fibrosis. Archived webcasts will be available on their website.
Read more →FDMT4DMT Appoints Kristian Humer as Chief Financial Officer
4D Molecular Therapeutics has appointed Kristian Humer as Chief Financial Officer. Humer brings over two decades of experience in corporate finance and strategic operations, having previously held senior roles at Citi and served as CFO for other biotech firms. His expertise is expected to support 4DMT's financial strategy as the company advances its Phase 3 programs.
Read more →FDMT4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (FDMT) reported its Q3 2025 financial results, highlighting progress in its clinical programs for 4D-150 and 4D-710. The company secured a partnership with Otsuka and received funding from the Cystic Fibrosis Foundation, extending its cash runway into the second half of 2028. Despite a net loss increase, the company remains optimistic about its ongoing Phase 3 trials and future milestones.
Read more →FDMTDMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercializat
4D Molecular Therapeutics (FDMT) reported its Q3 2025 financial results, highlighting a strategic partnership with Otsuka Pharmaceutical for the development of its 4D-150 product in the APAC region. The company will receive $85 million upfront and anticipates further contributions based on shared costs. Positive interim results from the Phase 1/2 PRISM clinical trial for wet AMD were also announced, supporting the efficacy and safety of its lead product. However, the company reported a net loss of $56.9 million for the quarter, reflecting increased R&D spending as it advances its trials.
Read more →FDMT4DMT to Participate in Jefferies 2025 London Healthcare Conference
4D Molecular Therapeutics (FDMT) announced its participation in the Jefferies 2025 London Healthcare Conference, where management will engage in a fireside chat and hold one-on-one meetings. The company is recognized for its late-stage biotechnology advancements, particularly in therapies for retinal diseases and cystic fibrosis. Archived webcasts of the event will be available on their website.
Read more →FDMT4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
4D Molecular Therapeutics has announced a $100 million underwritten offering of common stock and pre-funded warrants. The shares are priced at $10.51 each, with the offering expected to close on November 7, 2025. The funds raised will support the company's late-stage biotechnology initiatives, including treatments for retinal diseases and cystic fibrosis.
Read more →FDMT4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
4D Molecular Therapeutics announced positive interim data from the Phase 1/2 PRISM clinical trial of 4D-150, showing sustained visual acuity and reduced treatment burden in patients with wet AMD. The study demonstrated a consistent reduction in supplemental injections over a follow-up period of up to 2 years. The results suggest that 4D-150 could redefine treatment approaches for retinal diseases.
Read more →FDMT4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
4D Molecular Therapeutics has entered an exclusive licensing agreement with Otsuka Pharmaceutical to develop and commercialize 4D-150 for retinal diseases in the Asia-Pacific region. This partnership aims to leverage both companies' strengths to expedite the approval and commercialization of 4D-150, which targets wet AMD and DME. The deal includes an upfront payment and potential milestone payments, with 4DMT retaining rights outside the APAC region.
Read more →FDMT4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
4D Molecular Therapeutics (FDMT) will participate in Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025. The management team will engage in panel discussions and offer one-on-one meetings. The company is advancing its lead product candidate, 4D-150, for treating blinding retinal vascular diseases, currently in Phase 3 development.
Read more →FDMT▲ +8.7%on this newsshared move
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
4D Molecular Therapeutics has secured up to $11 million in funding from the Cystic Fibrosis Foundation to advance its gene therapy 4D-710 into Phase 2 clinical trials. This funding, which includes an initial $7.5 million, will support the development of 4D-710, aimed at treating cystic fibrosis lung disease. A Joint Steering Committee will also be established to enhance strategic guidance for the project.
Read more →FDMT4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
4D Molecular Therapeutics has expanded its leadership team to enhance the execution of its 4D-150 program and ensure readiness for a Biologics License Application (BLA). Dr. Julie Clark has been appointed as Chief Medical Officer, bringing significant experience in leading BLA submissions and Phase 3 trials. The company is optimistic about completing enrollment for its Phase 3 trial by Q1 2026.
Read more →FDMT4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Read more →FDMTDMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • 4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerat
4D Molecular Therapeutics (FDMT) reported its Q2 2025 financial results, highlighting advancements in its 4D-150 program for treating wet age-related macular degeneration (AMD). The data readout for the 4FRONT-1 trial has been accelerated to H1 2027 and additional trials have also been initiated ahead of schedule. Despite a reported net loss of $54.7 million, the company maintains a robust cash position that is projected to fund operations into 2028. The positive outcomes from recent clinical trials further underscore the therapeutic potential of 4D-150.
Read more →FDMT▼ -5.3%on this newsshared move
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Read more →FDMT4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
Read more →FDMT4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
Read more →FDMT4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
Read more →FDMTDMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinic
4D Molecular Therapeutics (FDMT) has announced its Q1 2025 financial results and provided operational highlights. Key achievements include the enrollment of the first patients in the 4D-150 Phase 3 clinical trial for wet AMD and the expected initiation of a second clinical trial in Q3 2025. The company also received RMAT designation from the FDA for 4D-150 in DME, further validating its therapeutic potential. Despite these advancements, the company reported a net loss of $48 million for the quarter, alongside a continued focus on its highest value programs.
Read more →FDMT4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Read more →FDMT4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
Read more →FDMT4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
Read more →FDMT4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Read more →FDMTDMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones • Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinic
4D Molecular Therapeutics (FDMT) reported strong financial and operational results for the year 2024, highlighting promising interim data from its PRISM and SPECTRA clinical trials. The data for 4D-150 indicated significant reductions in treatment burden for patients with wet AMD and diabetic macular edema (DME). Notably, the company stated its strategy to utilize existing cash reserves into 2028 while focusing on advancing key candidates. Upcoming milestones include the initiation of Phase 3 trials for 4D-150 in wet AMD and DME.
Read more →FDMTScrip Asks… What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends
The article discusses trends in clinical trials as part of a broader analysis of the biopharma landscape in 2025. It highlights the role of data science in transforming data gathering processes. The insights are part of a series by Scrip that aims to forecast future developments in the industry.
Read more →FDMT▼ -11%on this news· ran to -23% by day 1shared move
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
Read more →FDMT▲ +7.5%on this news· ran to +28% by day 3
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
Read more →FDMT4D-150 for DME moving to phase 3 trial following positive interim data
4D Molecular Therapeutics announced that its therapy 4D-150 has shown positive interim results in the SPECTRA trial for diabetic macular edema, prompting progression to a phase 3 trial. Patients receiving the highest dose experienced significant improvements in visual acuity and reduced treatment burden. The FDA has indicated that a single phase 3 trial is sufficient for biologics license application submission.
Read more →FDMTScrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry
The article discusses the current state of the biopharma industry and anticipates what 2025 may hold for it. It emphasizes the need for rigor in harnessing innovation to drive growth. The content is part of a series from Scrip that aims to provide insights into the biopharma sector.
Read more →FDMTLeveraging Directed Evolution To Optimize AAV Vector Design
4D Molecular Therapeutics (4DMT) is advancing gene therapy through directed evolution to optimize AAV vector design. The company aims to enhance specificity and transduction efficiency, which could lower production costs. With its lead candidate, 4D-150, entering Phase 3 for wet AMD in early 2025, 4DMT's methodical approach is yielding promising results.
Read more →FDMT▼ -5.5%on this news· ran to -18% by day 1shared move
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
Read more →FDMT▼ -5.5%on this news· ran to -18% by day 1shared move
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Read more →FDMT▼ -5.5%on this news· ran to -18% by day 1shared move
Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, includin
4D-150, a treatment for diabetic macular edema (DME), has demonstrated promising interim results. The clinical trial reported a sustained improvement in best corrected visual acuity with no observed serious side effects. Additionally, the FDA has approved the advancement of 4D-150 to Phase 3 clinical trials based on these interim findings. The product candidate is on track for a potential Biologics License Application submission.
Read more →FDMT4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
Read more →FDMT4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
Read more →FDMT4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Read more →FDMTDMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones • Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM P
4D Molecular Therapeutics (FDMT) reported strong third quarter 2024 financial results, highlighting positive interim data for its 4D-150 treatment in wet age-related macular degeneration (AMD) from the ongoing PRISM Phase 1/2 clinical trial. The company is on track to initiate its 4FRONT Phase 3 clinical trial in Q1 2025. 4DMT's financial position remains robust with $551 million in cash, ensuring operational funding well into 2027. The recent developments also include enhancements in their leadership team, aimed at expanding awareness and execution in ophthalmology treatments.
Read more →FDMTVIDEO: Intravitreally administered 4D-150 shows 90% reduction in wet AMD treatment burden
In a recent presentation at the Euretina congress, Dr. Anat Loewenstein discussed the promising results of 4D-150, a gene therapy for wet age-related macular degeneration (AMD). The phase 2 PRISM trial demonstrated that a single injection of 4D-150 can reduce the treatment burden by nearly 90% for patients previously reliant on multiple anti-VEGF injections. This advancement offers hope for more effective management of wet AMD.
Read more →FDMTDavid Kirn, Co-Founder & CEO, named a 2024 PharmaVoice 100 honoree in the Standout Leaders category
David Kirn, Co-Founder and CEO of FDMT, has been named a 2024 PharmaVoice 100 honoree in the Standout Leaders category. This recognition celebrates leaders who are reshaping the pharmaceutical industry through innovation and significant contributions. The PharmaVoice 100 list highlights various professionals across multiple categories, showcasing the ongoing transformation within the sector.
Read more →FDMTFresh data intensifies race for a major gene therapy target
4D Molecular Therapeutics has announced positive interim results from a mid-stage study for its gene therapy targeting wet AMD, showing a significant reduction in the need for standard injections. This positions the company for a pivotal phase 3 trial, intensifying competition in the wet AMD market, which is currently dominated by Regeneron's Eylea. Despite promising data, challenges such as high costs and competition from other therapies remain.
Read more →FDMT4DMT’s gene therapy reduced need for standard-of-care injections to treat age-associated vision loss
4D Molecular Therapeutics has reported positive results from a mid-stage trial of its gene therapy for age-related blindness. The therapy significantly reduced the need for standard injections in patients, suggesting it may offer a more effective treatment option. This development could enhance the quality of life for those suffering from vision loss.
Read more →FDMTIn race to make gene therapy for age-related blindness, 4D Molecular announces positive results
4D Molecular Therapeutics has reported promising results from its Phase 2 study on gene therapy for wet age-related macular degeneration. The therapy led to an 89% reduction in the need for standard injections, with 73% of patients not requiring further treatment for at least 32 weeks. The incidence of ocular inflammation was notably low among high-dose recipients, although the field has faced challenges in the past.
Read more →FDMT4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Read more →FDMT4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
Read more →FDMT4DMT Announces Presentations at Upcoming Retina Conferences
4DMT Announces Presentations at Upcoming Retina Conferences
Read more →FDMT4DMT to Participate in the 2024 Cantor Global Healthcare Conference
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
Read more →FDMT4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
Read more →FDMT4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Read more →FDMT4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
Read more →FDMTDMT Reports Second Quarter 2024 Financial Results and Operational Highlights • Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet
4D Molecular Therapeutics (FDMT) has reported positive interim results from its Phase 2 PRISM clinical trial for 4D-150, focusing on wet age-related macular degeneration (AMD). The company announced the formation of an Ophthalmology Advisory Board and has strengthened its leadership team to enhance its capabilities in ophthalmic drug development. Furthermore, the FDA has lifted the clinical hold on the Phase 1/2 INGLAXA study for 4D-310, allowing for resumed enrollment in the second half of 2024. With substantial cash reserves, the company is positioned to fund its operations through mid-2027.
Read more →FDMT▼ -6%on this newsshared move
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
Read more →FDMT▼ -32%on this news· ran to -43% by day 1
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
Read more →FDMTVIDEO: David Kirn, Co-Founder & CEO, 4DMT, provides an update on two candidates for retinal diseases
David Kirn, CEO of 4D Molecular Therapeutics, provided updates on two retinal disease candidates during a recent summit. The PRISM phase 2 trial for 4D-150 showed promising safety and efficacy results, including reduced need for anti-VEGF injections in wet AMD patients. The company has also filed for an investigational new drug application for 4D-175 targeting geographic atrophy and plans to initiate phase 3 trials in Q1 next year.
Read more →FDMT4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
Read more →FDMTVIDEO: ‘Excellent’ anatomic, vision control seen with 4D-150 at 24 weeks
In a recent analysis from the PRISM trial, Dr. Carl Danzig reported that patients receiving 4D-150 for wet age-related macular degeneration showed excellent anatomic and vision control. The high-dose group experienced an 89% reduction in treatment burden, with 63% of patients being injection-free. The safety of the treatment was also confirmed as excellent during the 24-week evaluation. A phase 3 trial is anticipated to begin in early 2025.
Read more →FDMTUneek Mehra speaks on a licensing and deal-making panel at BIO 2024
Uneek Mehra, CFO & CBO of FDMT, participated in a panel at BIO 2024 titled 'A Licensing Deal for All Seasons.' The discussion focused on the lifecycle of deals, motivations from both buyers and sellers, and the impact of the macro environment on partnerships in the biotech and pharmaceutical industries.
Read more →FDMTQ&A with David Kirn, Co-Founder & CEO, 4DMT
David Kirn, CEO of 4D Molecular Therapeutics, discusses the company's innovative use of directed evolution to develop customized viral vectors for gene therapy. The technology shows promise in treating various diseases, including rare genetic conditions and eye diseases. 4DMT has several products in clinical trials and aims to expand its reach in the coming years.
Read more →FDMT4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
Read more →FDMT4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
Read more →FDMT▼ -17.3%on this newsshared move
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
Read more →FDMT4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
Read more →FDMT4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47th European Cystic Fibrosis Conference
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47th European Cystic Fibrosis Conference
Read more →FDMT4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
Read more →FDMTDMT Reports First Quarter 2024 Financial Results and Operational Highlights • Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease acti
4D Molecular Therapeutics (FDMT) reported its first quarter 2024 financial results, highlighting significant operational achievements. The company announced promising interim data from its Phase 2 clinical trials for its lead candidate, 4D-150, in wet AMD patients, paving the way for a Phase 3 trial expected in Q1 2025. Additionally, the firm raised $337 million through a public offering, ensuring a strong financial position to support its ongoing clinical programs. Upcoming presentations of clinical data at various scientific meetings are also anticipated.
Read more →FDMTUsing Directed Evolution to Develop New Vectors for Genetic Medicines
4D Molecular Therapeutics is advancing genetic medicine by utilizing directed evolution to create a variety of synthetic adeno-associated viral vectors. This innovative approach aims to overcome the limitations of existing vectors, enhancing the delivery of therapies to target cells. The company is developing treatments for conditions such as cystic fibrosis and Fabry disease.
Read more →FDMT4DMT to Participate in Upcoming Investor Conference
4DMT to Participate in Upcoming Investor Conference
Read more →FDMT▲ +6.1%on this news
4DMT Announces Presentations at ARVO 2024 Annual Meeting
4DMT Announces Presentations at ARVO 2024 Annual Meeting
Read more →FDMTVectorized biologics: are patients and payers ready to swap biologics for gene therapies?
Gene therapy is evolving from a niche treatment for rare genetic disorders to a potential delivery system for various biologic drugs. Developers are optimistic about the clinical data supporting this shift, but significant hurdles remain in securing acceptance from patients, physicians, and payers. The promise of a one-time treatment could enhance patient adherence, yet the industry must navigate resistance to change.
Read more →FDMT▼ -11.2%on this news· ran to -22% by day 3
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
Read more →FDMT4DMT Reports Full Year 2023 Financial Results and Operational Highlights
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
Read more →FDMTDMT Reports Full Year 2023 Financial Results and Operational Highlights • Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with
4D Molecular Therapeutics (FDMT) reported its full-year 2023 financial results, highlighting significant advances across its product pipeline. Key interim data from the Phase 2 PRISM study demonstrated that 4D-150 showed efficacy in managing wet AMD, paving the way for a Phase 3 trial expected to start in Q1 2025. The company also reported robust cash reserves of $299 million and strategic collaborations aimed at enhancing their development in genetic medicines. Positive data from additional programs in cystic fibrosis and Fabry disease were also noted, indicating the potential breadth of their therapeutic capabilities.
Read more →FDMT4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium 2024
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium 2024
Read more →FDMT4D Molecular Therapeutics’ gene therapy cuts Eylea use in wet AMD patients, biotech divulges plans for pivotal studies
4D Molecular Therapeutics announced that its gene therapy for wet age-related macular degeneration (AMD) has resulted in reduced reliance on Eylea among patients. The company is preparing for pivotal studies to further evaluate the therapy's effectiveness. This development highlights the potential of gene therapy in treating AMD.
Read more →FDMT4DMT shares pipeline progress and the appointment of new CSO and SAB board members
4D Molecular Therapeutics (4DMT) has announced updates on its clinical pipeline, including expected timelines for trials involving treatments for wet AMD, DME, and geographic atrophy. The company plans to release critical datasets in 2024 and has appointed a new Chief Scientific Officer. Additionally, 4DMT's Phase 2 trials have received regulatory designations that may expedite their development.
Read more →FDMT▼ -15%on this newsshared move
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Read more →FDMT▲ +84.6%on this newsshared move
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
Read more →FDMT▲ +84.6%on this newsshared move
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
Read more →FDMTNavigating Platform vs Product Tension, David Kirn, Co-Founder & CEO, 4DMT
In a recent Biotech2050 podcast episode, David Kirn, CEO of 4D Molecular Therapeutics, discusses the integration of gene therapy and directed evolution in developing innovative treatments for genetic diseases. He highlights the importance of balancing a strong platform with diverse product opportunities to mitigate risks and enhance success probabilities in biotech. Kirn's insights provide essential guidance for aspiring entrepreneurs navigating the complexities of biotech investment.
Read more →FDMTScrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
The article discusses the future of biopharma in 2024, emphasizing the impact of transformative technologies, particularly artificial intelligence. It is part of a series exploring key trends and developments in the pharmaceutical industry. The insights aim to inform stakeholders about upcoming changes and innovations.
Read more →FDMT4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
Read more →FDMT4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
Read more →FDMTOne biotech’s 3 gene therapy hurdles: delivery, delivery and delivery
4D Molecular Therapeutics (4DMT) is advancing gene therapy by focusing on innovative delivery methods. CEO Dr. David Kirn emphasizes the importance of overcoming delivery challenges to enhance treatment efficacy. The company employs directed evolution technology to create optimized vectors, aiming to expand the application of gene therapy beyond rare diseases. With recent strategic hires and partnerships, 4DMT is positioned for significant growth in the field.
Read more →FDMTJ&J’s new partnership with Elektrofi; Enyo raises €39M; Arrowhead’s $450M offering
Johnson & Johnson has announced a partnership with Elektrofi, a Boston-based biotech firm, which aims to enhance drug delivery systems. Additionally, Enyo has successfully raised €39 million to support its research initiatives. The article also briefly mentions updates from TC BioPharm, BioCentrIQ, 4D Molecular, Arbor Biotechnologies, and Longboard Pharmaceuticals.
Read more →FDMT4D-710 leads to quality of life gains for CF patients in clinical trial
The inhaled gene therapy 4D-710 has demonstrated significant quality of life improvements for cystic fibrosis patients in a clinical trial. The therapy achieved higher than expected CFTR protein expression in lung cells. Initial results from the AEROW study indicate that 4D-710 is well tolerated, with no major safety concerns reported. The next phase of the trial will test a lower dose of the therapy.
Read more →FDMT4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
Read more →FDMT▼ -5.1%on this newsshared move
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Read more →FDMT▲ +7.3%on this news
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
Read more →FDMT4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
Read more →FDMT4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
Read more →FDMTDMT Reports Third Quarter 2023 Financial Results and Operational Highlights • Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expa
4D Molecular Therapeutics (FDMT) reported progress in its clinical trials and financial performance in Q3 2023. The company achieved early enrollment completion for the PRISM Phase 2 study of 4D-150 for wet AMD and received PRIME designation from the EMA. Additionally, positive interim results were shared from its 4D-710 clinical trial for cystic fibrosis. The financial update revealed a cash balance sufficient to sustain operations into the first half of 2026, highlighting a $320 million cash position.
Read more →FDMT4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
Read more →FDMT4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
Read more →FDMT4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
Read more →FDMT4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
Read more →FDMTUneek Mehra speaks on next-gen AAV panel at Chardan’s 7th Annual Genetic Medicines Conference
Uneek Mehra, CFO and CBO of FDMT, participated in a panel at the Chardan 7th Annual Genetic Medicines Conference. The discussion centered on next-generation AAVs and the potential of synthetic AAV capsids in enhancing genetic medicines. Esteemed leaders in the field shared valuable insights aimed at improving patient outcomes.
Read more →FDMTAstellas eyes rare ophthalmology, licensing 4DMT’s viral vector for gene therapy for up to $962M
Astellas has entered into a licensing agreement with 4D Molecular Therapeutics, paying $20 million upfront to utilize its viral vector technology for treating a rare monogenic eye disease. The total potential value of the deal could reach $962 million, indicating Astellas' commitment to expanding its capabilities in the ophthalmology sector.
Read more →FDMT4DMT’s inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients
4D Molecular Therapeutics announced that its inhalable gene therapy for cystic fibrosis demonstrated early positive signs of improved quality of life in a small patient group. This development could represent a significant advancement in the treatment of cystic fibrosis. Further details on the study and its implications are anticipated.
Read more →FDMTAerow hits the mark for 4D Molecular
The article provides an overview of resources and updates from Evaluate, focusing on their latest blogs, reports, and webinars in the biopharma market. It highlights the importance of staying informed about industry trends and insights. The content aims to engage readers by offering timely information and expert analysis.
Read more →FDMTReCode, Vertex and 4DMT Seek to Help Untreated Cystic Fibrosis Patients
ReCode, Vertex, and 4DMT are advancing treatments for the 6% of cystic fibrosis patients who do not produce CFTR protein. They are exploring mRNA therapies, gene therapies, and gene editing techniques to address this unmet need. While promising, these therapies face challenges such as immune responses and the need for frequent dosing.
Read more →FDMT5 Gene Therapy Companies That May Transform the Medical Industry
The article discusses the rapid growth of the gene therapy field, highlighting its potential to treat a variety of diseases through genetic modification. It outlines five key companies in the sector, including Bluebird Bio and CRISPR Therapeutics, each focusing on innovative therapies for conditions like cancer and diabetes. The gene therapy market is expected to reach a valuation of $13 billion by 2029, reflecting increasing investment and research in this area.
Read more →FDMT4D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary
4D Molecular Therapeutics has announced the acquisition of an eye disease asset from a subsidiary of Fortress Biotech. This move is part of 4DMT's strategy to enhance its product offerings in the ophthalmology sector. The acquisition reflects the company's commitment to addressing unmet needs in eye disease treatments.
Read more →FDMTThey were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help
Vertex Pharmaceuticals has significantly improved cystic fibrosis treatments, benefiting many patients. However, about 10% of patients remain without effective options due to specific genetic mutations. These patients continue to rely on older medications while their peers experience life-changing improvements. Vertex aims to address this gap in treatment.
Read more →FDMT#NACFC2022 – 4D-710 Safe, Restores CFTR Lung Production in 3 Patients
4D Molecular Therapeutics presented positive interim results for 4D-710, an aerosol gene therapy for cystic fibrosis, at the NACFC 2022. The therapy was reported safe and restored CFTR protein production in lung tissue from three patients in a Phase 1/2 trial. The study aims to enroll 21 patients, focusing on those not eligible for existing CFTR modulators.
Read more →FDMT4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
Read more →FDMT4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
Read more →FDMT4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
Read more →FDMTD Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age
4D Molecular Therapeutics has reported its second quarter 2023 financial results, highlighting significant progress in its clinical trials. The company presented positive interim data from the Phase 1/2 clinical trials of 4D-150 for wet AMD and 4D-710 for cystic fibrosis, with both showing promising tolerability and clinical activity. They completed target patient enrollment for the ongoing PRISM clinical trial earlier than expected. A robust financial standing was also noted, with $310 million in cash, poised to support operations into 2026.
Read more →FDMT4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
Read more →FDMT4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
Read more →FDMTAstellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets
Read more →FDMT4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
Read more →FDMT4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
Read more →FDMT4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
Read more →FDMT4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Read more →FDMT4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
Read more →FDMTD Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macula
4D Molecular Therapeutics reported its first quarter 2023 financial results, highlighting strong operational progress, particularly in their clinical trials for wet age-related macular degeneration (AMD). Positive interim data was presented from the Phase 1/2 PRISM clinical trial, showcasing excellent tolerability and clinical activity for the treatment. The company also secured $129 million in net proceeds from a public offering, which is expected to fund operations well into 2026. However, the increased net loss and rising R&D expenses pose ongoing financial challenges.
Read more →FDMT4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Read more →FDMT▼ -19.8%on this news
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
Read more →FDMT4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
Read more →FDMT▲ +11.1%on this news
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
Read more →FDMT▼ -6.1%on this news
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
Read more →FDMT▼ -6.1%on this news
D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights • Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabeti
4D Molecular Therapeutics reported its financial results for the full year 2022, highlighting updates on its clinical pipeline. The company is progressing with several product candidates, particularly 4D-150 for wet AMD and diabetic macular edema, and has maintained a strong cash position to fund its operations into 2025. While clinical trials have shown positive results, the company also reported a significant increase in net losses and a decrease in revenue due to the end of a collaboration agreement. With multiple data updates expected throughout 2023, 4DMT aims to further showcase the efficacy of its products.
Read more →FDMT4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium
Read more →FDMT4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium
Read more →FDMT▼ -5.5%on this news
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
Read more →FDMT▲ +7.3%on this news
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
Read more →FDMT▼ -10.2%on this news
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
Read more →FDMT▼ -5%on this news
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
Read more →FDMT▲ +7.8%on this news· ran to +79% by day 3
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
Read more →FDMT▲ +12.7%on this news· ran to +117% by day 3shared move
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
Read more →FDMT▲ +6.4%on this news· ran to +66% by day 3shared move
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
Read more →FDMT▲ +7.8%on this news
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
Read more →FDMT▲ +7.8%on this news
D Molecular Therapeutics Reports Third Quarter 2022 Financial Results - Interim clinical trial data from 4DMT's Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results - Interim clinical trial data from 4DMT's Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3, 2022 -
Read more →FDMT4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
Read more →FDMT4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
Read more →FDMTD Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update • Five clinical-stage product candidates on track for multiple clinical data updates in 2023 • Cash,
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update -Five clinical-stage product candidates on track for multiple clinical data updates in 2023 -Cash, cash equivalents and marketable securities sufficient to fund operations
Read more →FDMT4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update
Read more →FDMT4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences
4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences
Read more →FDMT4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
Read more →FDMTD Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates Emeryville, CA –
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates Emeryville, CA May 12, 2022 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted gene
Read more →FDMT▼ -8.7%on this news
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference
Read more →FDMT4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis
Read more →FDMT4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
Read more →FDMTD Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights — Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating p
Read more →FDMT4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company's Board of Directors
4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company's Board of Directors
Read more →FDMT▼ -9.9%on this news
4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Read more →FDMT4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium
4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium
Read more →FDMT4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium
4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium
Read more →FDMTHarnessing the Power of Directed Evolution for Targeted Gene Therapies Corporate Presentation | January 2022 2021 4D Molecular Therapeutics. All Rights Reserved. Legal Disclaimer This Presentation contains forward lookin
Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, stra
Read more →FDMT4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
Read more →FDMT4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
Read more →FDMT▼ -6.9%on this news
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
Read more →FDMTD Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights Emeryville, CA –
4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights Emeryville, CA November 10, 2021 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for t
Read more →FDMT4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights
4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights
Read more →FDMT▼ -22.1%on this news
4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
Read more →FDMT4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
Read more →FDMT▲ +13.5%on this news
4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
Read more →FDMT4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease
Read more →FDMT▼ -8.1%on this news
4D Molecular Therapeutics to Participate in Chardan's 5th Annual Genetic Medicines Conference
4D Molecular Therapeutics to Participate in Chardan's 5th Annual Genetic Medicines Conference
Read more →FDMT4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
Read more →FDMT4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights
4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights
Read more →FDMTD Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights Emeryville, CA
4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights Emeryville, CA - August 12, 2021 - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution fo
Read more →FDMT4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement
Read more →FDMTD Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement - 4D-110: Ini
Read more →FDMT4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
Read more →FDMT4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
Read more →FDMT4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
Read more →FDMTD Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights Emeryville, CA
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights Emeryville, CA - May 13, 2021 - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for ta
Read more →FDMT4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
Read more →FDMT4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
Read more →FDMT4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
Read more →FDMT4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies
Read more →FDMT4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
Read more →FDMTD Molecular Therapeutics Reports Financial Results for the Year Ended
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights - First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease - Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D
Read more →FDMT4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
Read more →FDMT4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Read more →FDMT4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering
4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering
Read more →FDMT4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development
4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development
Read more →FDMT4D Molecular Therapeutics Appoints Susannah Gray to Board of Directors
4D Molecular Therapeutics Appoints Susannah Gray to Board of Directors
Read more →FDMT4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa
Read more →FDMT4D Molecular Therapeutics Receives FDA Fast Track Designation for 4D-310 Gene Therapy for Treatment of Fabry Disease
4D Molecular Therapeutics Receives FDA Fast Track Designation for 4D-310 Gene Therapy for Treatment of Fabry Disease
Read more →FDMT4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia
Read more →FDMT4D Molecular Therapeutics Announces New Agreement With Cystic Fibrosis Foundation
4D Molecular Therapeutics Announces New Agreement With Cystic Fibrosis Foundation
Read more →FDMT4D Molecular Therapeutics Raises $75 Million in Series C Financing
4D Molecular Therapeutics Raises $75 Million in Series C Financing
Read more →FDMT4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update
4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update
Read more →FDMT4D Molecular Therapeutics Raises $90 Million Series B Financing
4D Molecular Therapeutics Raises $90 Million Series B Financing
Read more →FDMT4D Molecular Therapeutics Announces Collaboration with Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development
4D Molecular Therapeutics Announces Collaboration with Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development
Read more →FDMT4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
Read more →Competitive Position
How FDMT ranks across every disease it competes inCompetitive Position is a premium feature
See how FDMT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial